# OnCo record nct06162221 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06162221/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06162221", "NCT06162221" ;
  schema:name "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC"@en ;
  schema:description "A phase 1/2 trial of Elironrasib, Daraxonrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06162221/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06162221> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-01-18" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> .